Inclusion Criteria:

          1. Female patients >18 years of age must have a diagnosis of histologically confirmed
             Stage III/IV epithelial ovarian/fallopian tube/primary peritoneal adenocarcinoma who
             have not received any treatment or patients with recurrent Stage III/IV epithelial
             ovarian/tubal/peritoneal carcinoma with first recurrence ≥12 months after initial
             therapy and with resectable disease.

          2. All patients must have cytoreduction/laparoscopic surgery at UConn Health and their
             tissue must be stored in the UConn Health Center Research Tissue Registry/Repository
             (Biorepository) using cryopreservation methods.

          3. Patient must have completed standard platinum based adjuvant chemotherapy as per
             standard-of-care (only applicable for Vaccine Phase).

          4. Patients must have a life expectancy of at least 6 months.

          5. In the clinical judgment of the investigator, patients must have adequate renal,
             hepatic, and bone marrow function to complete the study:

               -  Hematologic function: Absolute neutrophil count (ANC) must be greater than 1000
                  per mcl. White blood count equal to or greater than 3000 per mcl, platelet count
                  greater than or equal to 100,000 per mcl.

               -  Renal function: Serum creatinine equal to or less than 2.0 mg/dl.

               -  Hepatic function: Bilirubin <1.5 x institutional normal.

          6. Patients with Patients with ECOG/WHO/Zubrod scale performance status < or = 2.

          7. No evidence of active infection.

          8. No evidence of active infection requiring systemic therapy. Patients enrolled in the
             Tissue and Blood Phase may receive IV antibiotics preoperatively, IV in surgery when
             they have a Hysterectomy and also postoperatively.

          9. Patients not participating in another experimental program/therapy at least 4 weeks
             prior to enrollment.

         10. Patients have enrolled and have adequate cancer tissue sample available from this
             cytoreduction/laparoscopic surgery deposited in the UConn Health Center Research
             Tissue Registry/Repository (Biorepository) study (Principal Investigator: Mary Melinda
             Sanders, MD; UConn Health IRB# 08-310-1) for this study.

         11. Patients must be English speaking and sign an approved informed consent form (ICF) and
             HIPAA.

        Exclusion Criteria:

          1. Patient not enrolled in the UConn Health Center Research Tissue Registry/Repository
             (Biorepository) study or there is inadequate tissue available for this study.

          2. Patients not in clinical remission after standard chemotherapy.

          3. Patients with recurrent Stage III/IV epithelial ovarian/tubal/peritoneal carcinoma
             with first recurrence < 12 months after initial therapy.

          4. Patients who have active autoimmune disease.

          5. Patients with any medical condition that would interfere with their ability to
             complete the study.

          6. Patients who are receiving any experimental drug therapy within 4 weeks of enrollment.

          7. Patients who are taking steroids (excludes topical steroids) within 4 weeks of
             enrollment.

          8. Patients with a prior malignancy within the previous 5 years or a synchronous primary
             cancer (non-melanoma skin cancer or other In Situ cancers are excluded).

          9. Patients unable or unwilling to provide informed consent.

         10. Patients whose tumors are not able to be sequenced or from which sufficient suitable
             neo- epitopes are not able to be identified.